WYNZORA (Betamethasone Dipropionate; Calcipotriene) Patent Expiration, LOE Window & CMS Spending

WYNZORA (Betamethasone Dipropionate; Calcipotriene) by Mc2 Therapeutics: FDA Orange Book core substance LOE 2039-03-18, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMc2 Therapeutics
FDA Application & PathwayN213422 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-03-18
Last Listed Patent or Exclusivity Date2039-03-18
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 13.9% 2-yr change)